Millie Das

2.2k total citations
63 papers, 719 citations indexed

About

Millie Das is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Millie Das has authored 63 papers receiving a total of 719 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Millie Das's work include Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Millie Das is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Millie Das collaborates with scholars based in United States, Canada and India. Millie Das's co-authors include Heather A. Wakelee, Joel W. Neal, Sukhmani K. Padda, Kavitha Ramchandran, Jessica A. Hellyer, Maximilian Diehn, Henning Stehr, Nathaniel J. Myall, Meera Vimala Ragavan and Jonathan W. Riess and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Millie Das

54 papers receiving 710 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Millie Das United States 17 405 388 287 145 68 63 719
Tianli Zhang China 14 294 0.7× 274 0.7× 236 0.8× 106 0.7× 56 0.8× 24 638
Caicun Zhou China 12 435 1.1× 393 1.0× 197 0.7× 106 0.7× 40 0.6× 36 710
Joseph Chen United States 13 452 1.1× 527 1.4× 240 0.8× 110 0.8× 34 0.5× 27 801
Xiuyi Zhi China 17 327 0.8× 355 0.9× 355 1.2× 164 1.1× 66 1.0× 66 874
Youwei Bi United States 14 275 0.7× 307 0.8× 225 0.8× 89 0.6× 49 0.7× 25 768
Francesca Casaluce Italy 15 512 1.3× 462 1.2× 326 1.1× 140 1.0× 62 0.9× 38 841
Jianzhong Cao China 15 253 0.6× 277 0.7× 232 0.8× 150 1.0× 45 0.7× 58 620
Kuan‐Yu Chen Taiwan 21 513 1.3× 579 1.5× 314 1.1× 163 1.1× 99 1.5× 39 1.1k
Cheng‐Bo Han China 17 381 0.9× 471 1.2× 270 0.9× 190 1.3× 41 0.6× 76 864
Andrzej Każarnowicz Poland 5 422 1.0× 304 0.8× 149 0.5× 83 0.6× 109 1.6× 14 578

Countries citing papers authored by Millie Das

Since Specialization
Citations

This map shows the geographic impact of Millie Das's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Millie Das with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Millie Das more than expected).

Fields of papers citing papers by Millie Das

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Millie Das. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Millie Das. The network helps show where Millie Das may publish in the future.

Co-authorship network of co-authors of Millie Das

This figure shows the co-authorship network connecting the top 25 collaborators of Millie Das. A scholar is included among the top collaborators of Millie Das based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Millie Das. Millie Das is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banwait, Mandeep K., Zofia Piotrowska, Karen Yun, et al.. (2025). Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer. Lung Cancer. 208. 108747–108747.
2.
Myall, Nathaniel J. & Millie Das. (2024). ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals. Current Problems in Cancer. 53. 101133–101133. 3 indexed citations
3.
Passero, Vida Almario, et al.. (2024). Teleoncology in the Veterans Health Administration: Models of Care and the Veteran Experience. American Society of Clinical Oncology Educational Book. 44(3). e100042–e100042. 3 indexed citations
4.
Levi, Jelena, Millie Das, Deepti Behl, et al.. (2024). [18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. Journal of Nuclear Medicine. 65(12). jnumed.124.268253–jnumed.124.268253. 1 indexed citations
5.
Hui, Caressa, Eleanor Brown, Millie Das, et al.. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. 25(2). 186–189. 1 indexed citations
6.
Patel, Shruti & Millie Das. (2023). Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. Cancers. 15(16). 4016–4016. 15 indexed citations
7.
Raja, N. Sri Madhava, Rie von Eyben, Millie Das, et al.. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology*Biology*Physics. 114(4). 603–610. 6 indexed citations
8.
Hellyer, Jessica A., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. 23(3). 264–272. 17 indexed citations
9.
Piper‐Vallillo, Andrew J., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. 23(3). e210–e221. 14 indexed citations
10.
Aredo, Jacqueline V., Sukhmani K. Padda, Kavitha Ramchandran, et al.. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer. 23(2). e148–e153. 20 indexed citations
11.
Hellyer, Jessica A., Jacqueline V. Aredo, Millie Das, et al.. (2021). Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 16(5). 868–872. 43 indexed citations
12.
Myall, Nathaniel J. & Millie Das. (2020). Advances in the Treatment of Stage III Non–Small Cell Lung Cancer. Clinics in Chest Medicine. 41(2). 211–222. 16 indexed citations
13.
Jeong, Youngtae, Jessica A. Hellyer, Henning Stehr, et al.. (2019). Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(1). 274–281. 80 indexed citations
14.
Hellyer, Jessica A., Henning Stehr, Millie Das, et al.. (2019). Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer. 134. 42–45. 34 indexed citations
15.
Patel, Jyoti D., Henry Wagner, D. Carbone, et al.. (2018). MA05.01 E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC. Journal of Thoracic Oncology. 13(10). S370–S370. 1 indexed citations
16.
Chuang, Jody C., Henning Stehr, Ying Liang, et al.. (2017). ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology. 12(5). 833–842. 60 indexed citations
17.
Riess, Jonathan W., Seema Nagpal, Millie Das, et al.. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases: Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. Journal of Thoracic Oncology. 8(2). e17–e18. 4 indexed citations
18.
Das, Millie & Heather A. Wakelee. (2012). Targeting VEGF in lung cancer. Expert Opinion on Therapeutic Targets. 16(4). 395–406. 31 indexed citations
19.
Das, Millie & Heather A. Wakelee. (2010). Vascular Disrupting Agents. Journal of Thoracic Oncology. 5(12). S482–S483. 3 indexed citations
20.
Das, Millie, M. Abdallah, Billy W. Loo, & Nishita Kothary. (2010). Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?. Current Treatment Options in Oncology. 11(1-2). 24–35. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tianli Zhang Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Joseph Chen Breakdown of academic impact, for papers by Xiuyi Zhi Breakdown of academic impact, for papers by Youwei Bi Breakdown of academic impact, for papers by Francesca Casaluce Breakdown of academic impact, for papers by Jianzhong Cao Breakdown of academic impact, for papers by Kuan‐Yu Chen Breakdown of academic impact, for papers by Cheng‐Bo Han Breakdown of academic impact, for papers by Andrzej Każarnowicz
Rankless by CCL
2026